

Thomas J George

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5386866/publications.pdf>

Version: 2024-02-01

197
papers

4,415
citations

136740

32
h-index

155451

55
g-index

203
all docs

203
docs citations

203
times ranked

7484
citing authors

#	ARTICLE	IF	CITATIONS
1	Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip. <i>Lab on A Chip</i> , 2014, 14, 89-98.	3.1	228
2	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€“Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	12.5	218
3	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 610-617.	0.6	192
4	Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1131-1141.	3.0	116
5	Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 275-280.	1.0	115
6	Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma. <i>Oncology Reports</i> , 2013, 29, 1259-1267.	1.2	108
7	Pancreas Cancer-Associated Weight Loss. <i>Oncologist</i> , 2019, 24, 691-701.	1.9	99
8	Adequacy of Published Oncology Randomized Controlled Trials to Provide Therapeutic Details Needed for Clinical Application. <i>Journal of the National Cancer Institute</i> , 2010, 102, 702-705.	3.0	92
9	Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management. <i>Clinical Colorectal Cancer</i> , 2018, 17, 1-12.	1.0	90
10	The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 205-213.	1.9	88
11	Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 892-910.	0.8	85
12	Extracting social determinants of health from electronic health records using natural language processing: a systematic review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 2716-2727.	2.2	84
13	Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2021, 7, 1225.	3.4	82
14	Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. <i>Annals of Oncology</i> , 2016, 27, 1336-1341.	0.6	78
15	Rectal cancer patients younger than 50 years lack a survival benefit from <sc>NCCN</sc> guidelineâ€“directed treatment for stage <sc>II</sc> and <sc>III</sc> disease. <i>Cancer</i> , 2018, 124, 3510-3519.	2.0	68
16	Oncologic and Perioperative Outcomes Following Selective Application of Laparoscopic Pancreaticoduodenectomy for Periampullary Malignancies. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1343-1349.	0.9	67
17	A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. <i>Oncology</i> , 2019, 97, 102-111.	0.9	67
18	Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. <i>Acta OncolÃ³gica</i> , 2013, 52, 498-505.	0.8	66

#	ARTICLE	IF	CITATIONS
19	Gemcitabine-Induced Reversible Posterior Leukoencephalopathy Syndrome: A Case Report and Review of the Literature. <i>Oncologist</i> , 2007, 12, 1332-1335.	1.9	62
20	Management of Malignant Bowel Obstruction Associated With GI Cancers. <i>Journal of Oncology Practice</i> , 2017, 13, 426-434.	2.5	60
21	Microfluidic Isolation of Circulating Tumor Cells and Cancer Stem-Like Cells from Patients with Pancreatic Ductal Adenocarcinoma. <i>Theranostics</i> , 2019, 9, 1417-1425.	4.6	58
22	Clinical Trial Generalizability Assessment in the Big Data Era: A Review. <i>Clinical and Translational Science</i> , 2020, 13, 675-684.	1.5	58
23	Integration of Lateral Filter Arrays with Immunoaffinity for Circulating Tumor Cell Isolation. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 7606-7610.	7.2	56
24	Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1436-1447.	0.8	53
25	Factors associated with parameters of engraftment potential of umbilical cord blood. <i>Transfusion</i> , 2006, 46, 1803-1812.	0.8	49
26	Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 861-867.	1.1	49
27	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34,640 Patients in the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 400-407.	3.0	44
28	5-FU induced cardiotoxicity: case series and review of the literature. <i>Cardio-Oncology</i> , 2019, 5, 13.	0.8	42
29	Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy. <i>Journal of the National Cancer Institute</i> , 2013, 105, 686-693.	3.0	40
30	Creating an mHealth App for Colorectal Cancer Screening: User-Centered Design Approach. <i>JMIR Human Factors</i> , 2019, 6, e12700.	1.0	40
31	Tobacco and E-cigarette use among cancer survivors in the United States. <i>PLoS ONE</i> , 2019, 14, e0226110.	1.1	39
32	Assessing the practice of data quality evaluation in a national clinical data research network through a systematic scoping review in the era of real-world data. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 1999-2010.	2.2	39
33	International Classification of Diseases, Tenth Revision, Clinical Modification social determinants of health codes are poorly used in electronic health records. <i>Medicine (United States)</i> , 2020, 99, e23818.	0.4	39
34	The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival. <i>BMC Cancer</i> , 2015, 15, 783.	1.1	37
35	An ontology-guided semantic data integration framework to support integrative data analysis of cancer survival. <i>BMC Medical Informatics and Decision Making</i> , 2018, 18, 41.	1.5	37
36	Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer. <i>Oncologist</i> , 2016, 21, 1306-1314.	1.9	36

#	ARTICLE	IF	CITATIONS
37	A clinically applicable muscular index predicts long-term survival in resectable pancreatic cancer. <i>Surgery</i> , 2017, 161, 930-938.	1.0	36
38	Adjuvant radiotherapy for cutaneous melanoma. <i>Cancer</i> , 2008, 112, 1189-1196.	2.0	33
39	Orthotopic Patient-Derived Pancreatic Cancer Xenografts Engraft Into the Pancreatic Parenchyma, Metastasize, and Induce Muscle Wasting to Recapitulate the Human Disease. <i>Pancreas</i> , 2017, 46, 813-819.	0.5	33
40	Body composition changes differ by gender in stomach, colorectal, and biliary cancer patients with cachexia: Results from a pilot study. <i>Cancer Medicine</i> , 2018, 7, 3695-3703.	1.3	33
41	Clinical Updates for Colon Cancer Care in 2022. <i>Clinical Colorectal Cancer</i> , 2022, 21, 198-203.	1.0	32
42	Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. <i>American Journal of Pathology</i> , 2016, 186, 1537-1546.	1.9	31
43	Landscape of <i>KRAS</i> ^{G12C} , Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in <i>KRAS</i> -Mutated Cancers. <i>JCO Precision Oncology</i> , 2022, 6, e2100245.	1.5	31
44	Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment. <i>Clinical Cancer Research</i> , 2016, 22, 1787-1799.	3.2	30
45	Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment. <i>The Journal of Supportive Oncology</i> , 2010, 8, 72-7.	2.3	30
46	Interobserver Variability of Mitotic Index and Utility of PHH3 for Risk Stratification in Gastrointestinal Stromal Tumors. <i>American Journal of Clinical Pathology</i> , 2015, 143, 385-392.	0.4	28
47	Rural-urban and racial-ethnic differences in awareness of direct-to-consumer genetic testing. <i>BMC Public Health</i> , 2018, 18, 277.	1.2	28
48	Randomized Clinical Trials in Colon and Rectal Cancer. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 689-704.	0.6	26
49	Engineering magnetic nanoparticles and their integration with microfluidics for cell isolation. <i>Journal of Colloid and Interface Science</i> , 2020, 564, 204-215.	5.0	26
50	NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)-First experimental arm (EA) initial results. <i>Journal of Clinical Oncology</i> , 2019, 37, 3505-3505.	0.8	26
51	Human pancreatic cancer xenografts recapitulate key aspects of cancer cachexia. <i>Oncotarget</i> , 2017, 8, 1177-1189.	0.8	26
52	Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1553-1563.	2.0	25
53	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1693-1704.	3.0	25
54	Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment. <i>Cancer Research</i> , 2017, 77, 672-683.	0.4	24

#	ARTICLE	IF	CITATIONS
55	How to Transition from Singleâ€Gene Pharmacogenetic Testing to Preemptive Panelâ€Based Testing: A Tutorial. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 557-565.	2.3	24
56	Hepatitis B Reactivation and Rituximab in the Oncology Practice. <i>Oncologist</i> , 2010, 15, 1113-1121.	1.9	23
57	Squamous Cell Carcinoma of the Anal Margin. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 406-410.	0.6	23
58	Neoadjuvant transarterial radiation lobectomy for colorectal hepatic metastases: a small cohort analysis on safety, efficacy, and radiopathologic correlation. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, E43-E51.	0.6	22
59	Non-surgical management of patients with intrahepatic cholangiocarcinoma in the United States, 2004â€2015: an NCDDB analysis. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 536-545.	0.6	22
60	Racial and ethnic disparities in a stateâ€wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. <i>Cancer Medicine</i> , 2019, 8, 3314-3324.	1.3	21
61	Analysis of the Cost Effectiveness of Laparoscopic Pancreatoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1404-1410.	0.9	21
62	The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials. <i>Frontiers in Oncology</i> , 2021, 11, 801379.	1.3	21
63	Predicting unintentional weight loss in patients with gastrointestinal cancer. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 526-535.	2.9	20
64	Eligibility Criteria Perpetuate Disparities in Enrollment and Participation of Black Patients in Pancreatic Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2022, 40, 2193-2202.	0.8	20
65	Use of Electronic Cigarettes Among Cancer Survivors in the U.S.. <i>American Journal of Preventive Medicine</i> , 2016, 51, 762-766.	1.6	19
66	The Proteome of Pancreatic Cancerâ€Derived Exosomes Reveals Signatures Rich in Key Signaling Pathways. <i>Proteomics</i> , 2019, 19, e1800394.	1.3	19
67	National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. <i>Cancer</i> , 2019, 125, 2732-2746.	2.0	19
68	Characteristics and outcomes of adenosquamous carcinoma of the pancreas. <i>Gastrointestinal Cancer Research: GCR</i> , 2013, 6, 75-9.	0.8	19
69	Small Molecule Inhibitor YM155-Mediated Activation of Death Receptor 5 Is Crucial for Chemotherapy-Induced Apoptosis in Pancreatic Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 80-89.	1.9	18
70	Standardization of surgical care in a high-volume center improves survival in resected pancreatic head cancer. <i>American Journal of Surgery</i> , 2016, 212, 195-201.e1.	0.9	18
71	Exploring the feasibility of using real-world data from a large clinical data research network to simulate clinical trials of Alzheimerâ€™s disease. <i>Npj Digital Medicine</i> , 2021, 4, 84.	5.7	18
72	A Pilot Study Examining the Efficacy of Delivering Colorectal Cancer Screening Messages via Virtual Health Assistants. <i>American Journal of Preventive Medicine</i> , 2021, 61, 251-255.	1.6	18

#	ARTICLE	IF	CITATIONS
73	Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 460-466.	3.0	17
74	Extragastrointestinal stromal tumors of the pelvic cavity and the vagina: Two case reports and review of the literature. <i>Gynecologic Oncology Reports</i> , 2018, 25, 3-7.	0.3	17
75	NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)â€™Pembrolizumab experimental arm (EA) primary results.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8-8.	0.8	17
76	Neoadjuvant rectal cancer (RC) score to predict survival: Potential surrogate endpoint for early phase trials.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3533-3533.	0.8	17
77	Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer. <i>Cancer Medicine</i> , 2015, 4, 1224-1239.	1.3	16
78	â€œIt is just another test they want to doâ€• Patient and caregiver understanding of the colonoscopy procedure. <i>Patient Education and Counseling</i> , 2016, 99, 651-658.	1.0	16
79	Design and rationale for the precision medicine guided treatment for cancer pain pragmatic clinical trial. <i>Contemporary Clinical Trials</i> , 2018, 68, 7-13.	0.8	16
80	Using photography to explore psychological distress in patients with pancreatic cancer and their caregivers: a qualitative study. <i>Supportive Care in Cancer</i> , 2019, 27, 321-328.	1.0	16
81	Incorporation of lateral microfiltration with immunoaffinity for enhancing the capture efficiency of rare cells. <i>Scientific Reports</i> , 2020, 10, 14210.	1.6	16
82	Neratinib-Plus-Cetuximab in Quadruple-WT (<i>KRAS, NRAS, BRAF, PIK3CA</i>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. <i>Clinical Cancer Research</i> , 2021, 27, 1612-1622.	3.2	16
83	A Phase II Trial of Neoadjuvant Capecitabine Combined With Hyperfractionated Accelerated Radiation Therapy in Locally Advanced Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 251-256.	0.6	16
84	Influential factors on treatment decision making among patients with colorectal cancer: A scoping review. <i>Supportive Care in Cancer</i> , 2017, 25, 2943-2951.	1.0	15
85	Augmentation of Cancer Cachexia Components With Targeted Acupuncture in Patients With Gastrointestinal Cancers: A Randomized Controlled Pilot Study. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541882326.	0.8	14
86	Disparities in Pancreatic Ductal Adenocarcinomaâ€™The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes. <i>Cancer Medicine</i> , 2020, 9, 4069-4082.	1.3	14
87	Tailoring virtual humanâ€™delivered interventions: A digital intervention promoting colorectal cancer screening for Black women. <i>Psycho-Oncology</i> , 2020, 29, 2048-2056.	1.0	14
88	The Influence of Patient Identification and Narrative Transportation on Intentions to Participate in Cancer Research. <i>Journal of Cancer Education</i> , 2019, 34, 725-734.	0.6	13
89	Key changes to improve social presence of a virtual health assistant promoting colorectal cancer screening informed by a technology acceptance model. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 196.	1.5	13
90	NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations. <i>Oncotarget</i> , 2017, 8, 57246-57264.	0.8	13

#	ARTICLE	IF	CITATIONS
91	Facilitation or Hindrance: Physicians' Perception on Best Practice Alerts (BPA) Usage in an Electronic Health Record System. <i>Health Communication</i> , 2019, 34, 942-948.	1.8	12
92	Rural-urban disparities in tobacco retail access in the southeastern United States: CVS vs. the dollar stores. <i>Preventive Medicine Reports</i> , 2019, 15, 100935.	0.8	12
93	Characteristics and outcomes of adenosquamous carcinoma of the pancreas. <i>Journal of Clinical Oncology</i> , 2013, 31, 311-311.	0.8	12
94	NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS261-TPS261.	0.8	12
95	Stereotactic body radiation therapy for oligoprogression of metastatic disease from gastrointestinal cancers: A novel approach to extend chemotherapy efficacy. <i>Oncology Letters</i> , 2017, 13, 1087-1094.	0.8	11
96	Data integration through ontology-based data access to support integrative data analysis: A case study of cancer survival. , 2017, 2017, 1300-1303.		11
97	Clinical Factors as a Component of the Personalized Treatment Approach to Advanced Pancreatic Cancer: a Systematic Literature Review. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 1-8.	0.6	11
98	A Phase Ib study of ruxolitinib + gemcitabine & nab-paclitaxel in patients with advanced solid tumors. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2399-2407.	1.0	11
99	Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma. <i>Oncologist</i> , 2021, 26, 825-e1674.	1.9	11
100	Internet-based tailored virtual human health intervention to promote colorectal cancer screening: design guidelines from two user studies. <i>Journal on Multimodal User Interfaces</i> , 2021, 15, 147-162.	2.0	11
101	Predictive validity of NeoAdjuvant Rectal (NAR) Score and pathologic complete response (ypCR) for overall survival (OS) as surrogate endpoints in rectal cancer clinical trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 3533-3533.	0.8	10
102	Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2014, 32, 682-690.	1.2	9
103	A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. <i>OncoTargets and Therapy</i> , 2015, 8, 3561.	1.0	9
104	Radiotherapy in the Treatment of Resectable Rectal Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 629-638.	0.6	8
105	Definitive Radiotherapy for Squamous Cell Carcinoma of the Anal Canal. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 47-51.	0.6	8
106	Gastroduodenal Ulcerations As a Delayed Complication of Hepatic Metastasis Radioembolization. <i>Journal of Clinical Oncology</i> , 2010, 28, e735-e736.	0.8	8
107	A Novel Microfluidic Device for Isolation of Circulating Tumor Cells from Pancreatic Cancer Blood Samples. <i>Methods in Molecular Biology</i> , 2017, 1634, 33-53.	0.4	8
108	Comprehensive literature review of randomized clinical trials examining novel treatment advances in patients with colon cancer. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 790-802.	0.6	8

#	ARTICLE	IF	CITATIONS
109	A Subjective Culture Approach to Cancer Prevention: Rural Black and White Adultsâ€™ Perceptions of Using Virtual Health Assistants to Promote Colorectal Cancer Screening. <i>Health Communication</i> , 2022, 37, 1123-1134.	1.8	8
110	Immunotherapy Management in Special Cancer Patient Populations. <i>JCO Oncology Practice</i> , 2021, 17, 240-245.	1.4	8
111	â€œTissue is the Issueâ€: Circulating Tumor Cells in Pancreatic Cancer. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 222-225.	0.6	7
112	Src Inhibition Is Still a Relevant Target in Pancreatic Cancer. <i>Oncologist</i> , 2014, 19, 211-211.	1.9	7
113	Objective Preoperative Parameters Predict Difficult Pelvic Dissections and Clinical Outcomes. <i>Journal of Surgical Research</i> , 2018, 232, 15-25.	0.8	7
114	Integration of Lateral Filter Arrays with Immunoaffinity for Circulatingâ€™Tumorâ€™Cell Isolation. <i>Angewandte Chemie</i> , 2019, 131, 7688-7692.	1.6	7
115	Assessing the effect of data integration on predictive ability of cancer survival models. <i>Health Informatics Journal</i> , 2020, 26, 8-20.	1.1	7
116	Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2717-2723.e3.	2.4	7
117	A Comprehensive Review of Randomized Clinical Trials Shaping the Landscape of Rectal Cancer Therapy. <i>Clinical Colorectal Cancer</i> , 2021, 20, 1-19.	1.0	7
118	The Florida Pancreas Collaborative Next-Generation Biobank: Infrastructure to Reduce Disparities and Improve Survival for a Diverse Cohort of Patients with Pancreatic Cancer. <i>Cancers</i> , 2021, 13, 809.	1.7	7
119	The association between cognitive impairment and breast and colorectal cancer screening utilization. <i>BMC Cancer</i> , 2021, 21, 539.	1.1	7
120	New onset of type 2 diabetes as a complication after cancer diagnosis: A systematic review. <i>Cancer Medicine</i> , 2021, 10, 439-446.	1.3	7
121	Osteopenia is associated with wasting in pancreatic adenocarcinoma and predicts survival after surgery. <i>Cancer Medicine</i> , 2022, 11, 50-60.	1.3	7
122	Protocol Information Provides Opportunity for Patient Safety and Quality Improvement. <i>Journal of Clinical Oncology</i> , 2011, 29, e563-e563.	0.8	6
123	Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification. <i>Oncoscience</i> , 2015, 2, 581-584.	0.9	6
124	EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 838-847.	0.6	6
125	Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOGâ€™ACRIN Cancer Research Group (E4203). <i>Cancer</i> , 2018, 124, 688-697.	2.0	6
126	Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)â€™NRC-GI004/SWOG-S1610.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS3618-TPS3618.	0.8	6

#	ARTICLE	IF	CITATIONS
127	Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2019, 37, TPS728-TPS728.	0.8	6
128	Longitudinal Study of Circulating Biomarkers in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Biosensors, 2022, 12, 206.	2.3	6
129	Argininosuccinate synthase as a novel biomarker for inflammatory conditions. Biomarkers, 2013, 18, 242-249.	0.9	5
130	Pathways to Colonoscopy in the South: Seeds of Health Disparities. American Journal of Public Health, 2015, 105, e103-e111.	1.5	5
131	Clinical, morphologic, and immunophenotypic characteristics of ampullary carcinomas with an emphasis on SMAD4 expression. Journal of Gastrointestinal Oncology, 2016, 6, 974-981.	0.6	5
132	Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group. Journal of Clinical Oncology, 2016, 34, 186-193.	0.8	5
133	Cancer Hallmark-Based Gene Sets and Personalized Medicine for Patients With Stage II Colon Cancer. JAMA Oncology, 2016, 2, 23.	3.4	5
134	The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma. Current Treatment Options in Oncology, 2017, 18, 73.	1.3	5
135	A Pilot Study Determining Comprehension and the Acceptability of a Cancer Research Study Website for Cancer Patients and Caregivers. Journal of Cancer Education, 2020, 35, 589-598.	0.6	5
136	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. Journal of the National Cancer Institute, 2022, 114, 60-67.	3.0	5
137	NRG-GI002: A phase II clinical trial platform for total neoadjuvant therapy (TNT) in rectal cancer.. Journal of Clinical Oncology, 2017, 35, TPS3629-TPS3629.	0.8	5
138	NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or n plus cetuximab (C) in patients (pts) with "quadruple wild-type (WT)" (KRAS/NRAS/BRAF/PIK3CA WT) metastatic colorectal cancer (mCRC) based on HER2 status—Amplified (amp), non-amplified (non-amp), WT, or mutated (mt).. Journal of Clinical Oncology, 2019, 37, TPS716-TPS716.	0.8	5
139	Development of a Credible Virtual Clinician Promoting Colorectal Cancer Screening via Telehealth Apps for and by Black Men: Qualitative Study. JMIR Formative Research, 2021, 5, e28709.	0.7	5
140	Bisphosphonate-induced osteonecrosis of the jaw: long-term outcomes. The Journal of Supportive Oncology, 2009, 7, 9-10.	2.3	5
141	Rationale and appropriate use of chemotherapy and radiotherapy for pancreatic ductal adenocarcinoma. Current Gastroenterology Reports, 2006, 8, 111-120.	1.1	4
142	KRAS mutational analysis: ready for prime time?. Community Oncology, 2008, 5, 435-436.	0.2	4
143	Two Cases of Rare Pancreatic Malignancies. Journal of Pancreatic Cancer, 2019, 5, 26-33.	1.6	4
144	Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer. Oncologist, 2021, 26, 362-e724.	1.9	4

#	ARTICLE	IF	CITATIONS
145	A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610).. Journal of Clinical Oncology, 2020, 38, TPS360-TPS369.	0.8	4
146	Assessing the Validity of a Patient-Trial Generalizability Score using Real-world Data from a Large Clinical Data Research Network: A Colorectal Cancer Clinical Trial Case Study. AMIA ... Annual Symposium proceedings, 2019, 2019, 1101-1110.	0.2	4
147	Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know. Cancer Treatment Reviews, 2022, 105, 102376.	3.4	4
148	Assessing the population representativeness of colorectal cancer treatment clinical trials. , 2016, 2016, 2970-2973.		3
149	Innovation or Inconsistency? Framing Colorectal Cancer Guidelines to Improve Public Perceptions of Updated Screening Recommendations. Journal of Language and Social Psychology, 2017, 36, 14-27.	1.2	3
150	Providers' Perceptions of Barriers to Optimal Communication With Patients During the Postcolonoscopy Experience. Journal of Patient Experience, 2018, 5, 272-278.	0.4	3
151	A phase II clinical trial platform utilizing total neoadjuvant therapy (TNT) in rectal cancer: Nrg-GI002.. Journal of Clinical Oncology, 2016, 34, TPS3638-TPS3638.	0.8	3
152	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. Journal of Clinical Oncology, 2020, 38, TPS4121-TPS4121.	0.8	3
153	Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma. Journal of Gastrointestinal Oncology, 2016, 7, 173-80.	0.6	3
154	Using Real-World Data to Rationalize Clinical Trials Eligibility Criteria Design: A Case Study of Alzheimer's Disease Trials. AMIA ... Annual Symposium proceedings, 2020, 2020, 717-726.	0.2	3
155	NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study. A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2022, 40, TPS232-TPS232.	0.8	3
156	Communicating risk to promote colorectal cancer screening: a multi-method study to test tailored versus targeted message strategies. Health Education Research, 2022, 37, 79-93.	1.0	3
157	Telehealth and racial disparities in colorectal cancer screening: A pilot study of how virtual clinician characteristics influence screening intentions. Journal of Clinical and Translational Science, 2022, 6, .	0.3	3
158	Tumor cell isolation in microfluidic devices for cancer treatment monitoring. , 2017, , .		2
159	Thermal ablation versus wedge or segmental resection in patients with early stage hepatocellular carcinoma: a population survival analysis. Hpb, 2019, 21, 249-257.	0.1	2
160	Differential response to targeted acupuncture by gender in patients with gastrointestinal cancer cachexia: secondary analysis of a randomized controlled trial. Acupuncture in Medicine, 2020, 38, 53-60.	0.4	2
161	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).. Journal of Clinical Oncology, 2021, 39, TPS148-TPS148.	0.8	2
162	Utilizing total neoadjuvant therapy (TNT) in rectal cancer: NRG-GI002, a phase II clinical trial platform.. Journal of Clinical Oncology, 2017, 35, TPS814-TPS814.	0.8	2

#	ARTICLE	IF	CITATIONS
163	Cancer Survivorâ€™s History and Physical. Southern Medical Journal, 2017, 110, 37-44.	0.3	2
164	Administration of Immune Checkpoint Inhibitors Near the End of Life. JCO Oncology Practice, 2022, 18, e849-e856.	1.4	2
165	Adjuvant High-Dose Interferon-Î± for Resected Melanoma in a Patient with HIV Infection. Oncologist, 2010, 15, 695-698.	1.9	1
166	Multiagent Regimens for Metastatic Colorectal Cancer: If Some Is Good, More Must Be Better. Journal of the National Cancer Institute, 2011, 103, 4-5.	3.0	1
167	Sociodemographic factors associated with stage of diagnosis and treatment uptake among patients with colorectal cancer: A brief report. Journal of Cancer Policy, 2017, 12, 79-82.	0.6	1
168	Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 404-411.	1.1	1
169	Impact of An Annual Hematology/Oncology Fellow Wet Laboratory Program On Fund of Biomedical Knowledge.. Blood, 2009, 114, 246-246.	0.6	1
170	Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer: NSABP FR-2.. Journal of Clinical Oncology, 2019, 37, TPS3620-TPS3620.	0.8	1
171	Comment on â€œA National Cancer Database Analysis of Microsatellite Instability and Pathologic Complete Response in Locally Advanced Rectal Cancerâ€. Annals of Surgery, 2020, Publish Ahead of Print, e197-e198.	2.1	1
172	Pancreatic heterotopia masquerading as duodenal carcinoid. Gastrointestinal Cancer Research: GCR, 2009, 3, 118-20.	0.8	1
173	Using circulating tumor DNA for colon cancer adjuvant therapy: to be or not to be?. Clinical Cancer Research, 2021, , clincanres.3564.2021.	3.2	1
174	Comparison of sample preparation methods for rare cell isolation in microfluidic devices. Canadian Journal of Chemistry, 2022, 100, 512-519.	0.6	1
175	Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).. Journal of Clinical Oncology, 2022, 40, TPS233-TPS233.	0.8	1
176	Efficacy of SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, 575-575.	0.8	1
177	Explore Care Pathways of Colorectal Cancer Patients with Social Network Analysis. Studies in Health Technology and Informatics, 2017, 245, 1270.	0.2	1
178	Welcome to the team: trastuzumab in HER2-positive esophagogastric cancers. Community Oncology, 2009, 6, 544-545.	0.2	0
179	Fellowship Engagement in Hematology/Oncology Professionalism Training. Journal of Clinical Oncology, 2014, 32, 1164-1166.	0.8	0
180	A New Predictive Molecular Marker for Cetuximab Benefit in Rectal Cancer?. Journal of the National Cancer Institute, 2014, 106, .	3.0	0

#	ARTICLE	IF	CITATIONS
181	Infusion Room-Based Transition to Practice Model for Teaching Cancer Systemic Therapy Management. <i>Journal of Oncology Practice</i> , 2017, 13, e909-e915.	2.5	0
182	Should Upfront Chemotherapy Precede Preoperative Chemoradiotherapy and Surgery in Locally Advanced Rectal Cancer?. , 2018, , 287-297.		0
183	InnenrÄ¼cktitelbild: Integration of Lateral Filter Arrays with Immunoaffinity for Circulatingâ€Tumorâ€Cell Isolation (<i>Angew. Chem.</i> 23/2019). <i>Angewandte Chemie</i> , 2019, 131, 7961-7961.	1.6	0
184	A Statistical Method for Association Analysis of Cell Type Compositions. <i>Statistics in Biosciences</i> , 2021, 13, 373-385.	0.6	0
185	Establishing and Evaluating an ASCO Learning Cohort: a Longitudinal Project Assessing the Learning Needs and Behaviors of Oncology Professionals. <i>Journal of Cancer Education</i> , 2021, 36, 478-483.	0.6	0
186	Systematic Analysis of Extracting Data on Advance Directives from Patient Electronic Health Records (EHR) in Terminal Oncology Patients. <i>Journal of Palliative Care</i> , 2021, 36, 211-218.	0.4	0
187	A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study) (NCT03483038).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4170-TPS4170.	0.8	0
188	Utility of Restaging MRI Following Neoadjuvant Chemoradiotherapy for Stage II-III Rectal Adenocarcinoma. <i>Cureus</i> , 2021, 13, e19037.	0.2	0
189	A phase II clinical trial platform for sensitization testing using total neoadjuvant therapy (TNT) in rectal cancer: Nrg-GI002.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS721-TPS721.	0.8	0
190	Impact of preoperative chemoradiotherapy (CRT) on the rectal tumor microenvironment (TME) and associated patient outcomes.. <i>Journal of Clinical Oncology</i> , 2022, 40, 157-157.	0.8	0
191	A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS619-TPS619.	0.8	0
192	Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev.. <i>Journal of Clinical Oncology</i> , 2022, 40, 140-140.	0.8	0
193	It's Tough to Make Predictions, Especially About the Future ... of Rectal Cancer. <i>Oncology</i> , 2016, 30, 563-4.	0.4	0
194	NRG GI002: Moving the needle toward TNT in locally advanced rectal cancer. <i>Bulletin of the American College of Surgeons</i> , 2016, 101, 61-2.	0.3	0
195	Validation of Real-World Data-based Endpoint Measures of Cancer Treatment Outcomes.. <i>AMIA ... Annual Symposium proceedings</i> , 2021, 2021, 716-725.	0.2	0
196	Using T stage to predict outcomes of adjuvant oxaliplatin (OX)-based chemotherapy (CT) in stage III colon cancer (CC): An ACCENT pooled analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3606-3606.	0.8	0
197	Simulating Colorectal Cancer Trials Using Real-World Data. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	1.0	0